# Combined resistance exercise and essential amino acid intake enhance follistatin/myostatin ratio and muscle fitness in older women: a randomized controlled trial

**Authors:** Deokhwa Jeong, Rudy J. Valentine, Hyeongmo Jeong, Jun-Young Sung, Heekyoung Lim, Sunghwun Kang

PMC · DOI: 10.1080/15502783.2026.2646626 · Journal of the International Society of Sports Nutrition · 2026-03-21

## TL;DR

Combining resistance exercise and essential amino acids improves muscle mass and fitness in older women more than either alone.

## Contribution

First randomized trial showing combined resistance exercise and EAA supplementation enhances muscle health in healthy elderly women.

## Key findings

- The RE + EAA group showed significant increases in muscle mass and senior fitness test performance.
- The follistatin/myostatin ratio increased most in the RE + EAA group compared to other groups.
- Inflammatory markers like IL-6 and TNF-α were reduced in the RE + EAA group.

## Abstract

Age-associated sarcopenia and declining physical function in older women are connected to changes in hormones, inflammation, and disrupted protein metabolism. Myokines and cytokines play central roles in muscle atrophy. While both resistance exercise (RE) and essential amino acid (EAA) supplementation are promising interventions, limited randomized trials have assessed their combined effect in healthy elderly populations. Early targeted strategies may help delay sarcopenia and promote healthier aging.

A 12-week randomized controlled trial was performed involving 96 healthy women aged ≥ 65 years without insulin resistance. Participants were randomized into four groups: control, RE, EAA, or RE + EAA. The intervention consisted of a circuit-based training program conducted three times per week, with each session lasting 60 minutes at moderate intensity. Participants in EAA and RE + EAA groups consumed 5.5g of EAA twice daily. Assessments before and after the intervention included body composition, muscle fitness, serum myokines, and inflammatory cytokines. Data analysis involved two-way repeated measures ANOVA, Bonferroni post-hoc comparisons, and one-way ANOVA for changes in the follistatin/myostatin ratio.

The RE + EAA group demonstrated a significant increase in muscle mass (F(3, 72) = 5.042, p < 0.001, partial η² = 0.174) and greater improvements in the senior fitness test (p ranging from < 0.05 to < 0.001). There was a reduction in myostatin levels (p < 0.05) and an elevation in follistatin in both the RE (p < 0.05) and RE + EAA (p < 0.001) groups. The follistatin/myostatin ratio increased most in the RE + EAA group (F(3, 72) = 5.556, p = 0.002, partial η² = 0.188), with significance versus control (p < 0.001), EAA (p < 0.05) groups. IL-6 and IL-1β were significantly reduced in the RE (p < 0.05) and RE + EAA (p < 0.05) groups, whereas TNF-α decreased only in the RE + EAA group (p < 0.05).

A 12-week intervention combining resistance exercise and essential amino acid supplementation was superior to either intervention alone in enhancing muscle mass, muscle fitness, myokine profiles, and reducing inflammatory markers among healthy older women. These results support the development of early combined interventions for the prevention of sarcopenia and may guide personalized exercise-nutrition prescriptions for optimal aging.

KCT 0010756 (Retrospectively registered; July 15, 2025).

## Linked entities

- **Proteins:** LOC5521725 (growth/differentiation factor 8), LOC5564573 (agrin), IL6 (interleukin 6), IL1B (interleukin 1 beta), TNF (tumor necrosis factor)

## Full-text entities

- **Genes:** NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, MYOD1 (myogenic differentiation 1) [NCBI Gene 4654] {aka CMYO17, CMYP17, MYF3, MYOD, MYODRIF, PUM}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, ACVR2B (activin A receptor type 2B) [NCBI Gene 93] {aka ACTRIIB, ActR-IIB, HTX4}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, FNDC5 (fibronectin type III domain containing 5) [NCBI Gene 252995] {aka FRCP2, irisin}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1) [NCBI Gene 5562] {aka AMPK, AMPK alpha 1, AMPKa1}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, SESN2 (sestrin 2) [NCBI Gene 83667] {aka HI95, SES2, SEST2}, FST (follistatin) [NCBI Gene 10468] {aka FS}, IL15 (interleukin 15) [NCBI Gene 3600] {aka IL-15}, MSTN (myostatin) [NCBI Gene 2660] {aka GDF8, MSLHP}
- **Diseases:** loss of muscle mass (MESH:C536030), musculoskeletal disorder (MESH:D009140), muscle loss (MESH:D009135), Insulin Resistance (MESH:D007333), metabolic disorders (MESH:D008659), insomnia (MESH:D007319), Sarcopenia (MESH:D055948), hypertrophic (MESH:D002312), type 2 diabetes (MESH:D003924), cancer (MESH:D009369), weight loss (MESH:D015431), depression (MESH:D003866), low (MESH:D009800), impaired physical capacity (MESH:D059445), hypertrophy (MESH:D006984), cardiovascular disease (MESH:D002318), MPB (MESH:D019042), metabolic disturbances (MESH:D024821), muscle atrophy (MESH:D009133), visceral adiposity (MESH:D007418), anxiety (MESH:D001007), frailty (MESH:D000073496), inflammation (MESH:D007249), muscle hypertrophy (MESH:C536106)
- **Chemicals:** RE (-), leucine (MESH:D007930), amino acid (MESH:D000596), water (MESH:D014867), lipid (MESH:D008055), EAA (MESH:D000601), nitrogen (MESH:D009584), glucose (MESH:D005947)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13007441/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13007441/full.md

## References

49 references — full list in the complete paper: https://tomesphere.com/paper/PMC13007441/full.md

---
Source: https://tomesphere.com/paper/PMC13007441